Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear